Evidence map›Paper›PMID 40359934›Full record

ArticleCell reports. Medicine2025

Organoid morphology-guided classification for oral cancer reveals prognosis.

Mi Rim Lee, Sumin Kang, Jonghyun Lee, Sun-Young Kong, Youngwook Kim, Yu-Sun Lee, Hye Won Shon, Gyeongmin Kang, Jiyoung Lee, Suk Min Youn and 9 more

Abstract read
In one paragraph

Article in Cell reports. Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Mi Rim LeeMolecular Imaging Branch, Division of Convergence Technology, Research Institute of National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang, Gyeonggi-do 10408, Republic of Korea; Department of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, 323 Ilsan-ro, Ilsandong-gu, Goyang, Gyeonggi-do 10408, Republic of Korea.
Sumin KangMolecular Imaging Branch, Division of Convergence Technology, Research Institute of National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang, Gyeonggi-do 10408, Republic of Korea; Department of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, 323 Ilsan-ro, Ilsandong-gu, Goyang, Gyeonggi-do 10408, Republic of Korea.
Jonghyun LeeBioinformatics Branch, Division of Cancer Data Science, Research Institute of National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang, Gyeonggi-do 10408, Republic of Korea.
Sun-Young KongDepartment of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, 323 Ilsan-ro, Ilsandong-gu, Goyang, Gyeonggi-do 10408, Republic of Korea; Targeted Therapy Branch, Division of Rare and Refractory Cancer, Research Institute of National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang, Gyeonggi-do 10408, Republic of Korea; Department of Laboratory Medicine, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang, Gyeonggi-do 10408, Republic of Korea.
Youngwook KimDepartment of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, 323 Ilsan-ro, Ilsandong-gu, Goyang, Gyeonggi-do 10408, Republic of Korea.
Yu-Sun LeeMolecular Imaging Branch, Division of Convergence Technology, Research Institute of National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang, Gyeonggi-do 10408, Republic of Korea.
Hye Won ShonMolecular Imaging Branch, Division of Convergence Technology, Research Institute of National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang, Gyeonggi-do 10408, Republic of Korea.
Gyeongmin KangMolecular Imaging Branch, Division of Convergence Technology, Research Institute of National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang, Gyeonggi-do 10408, Republic of Korea; Department of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, 323 Ilsan-ro, Ilsandong-gu, Goyang, Gyeonggi-do 10408, Republic of Korea.
Jiyoung LeeMolecular Imaging Branch, Division of Convergence Technology, Research Institute of National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang, Gyeonggi-do 10408, Republic of Korea.
Suk Min YounOral Oncology Clinic, Research Institute and Hospital, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang, Gyeonggi-do 10408, Republic of Korea.
Da Woon KwackOral Oncology Clinic, Research Institute and Hospital, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang, Gyeonggi-do 10408, Republic of Korea.
Joo Yong ParkOral Oncology Clinic, Research Institute and Hospital, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang, Gyeonggi-do 10408, Republic of Korea.
Soung Min KimDepartment of Oral and Maxillofacial Surgery, Seoul National University Dental Hospital, Dental Research Institute, School of Dentistry, Seoul National University, 101 Daehak-ro, Jongno-gu, Seoul 03080, Republic of Korea.
Wonyoung ChoiDepartment of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, 323 Ilsan-ro, Ilsandong-gu, Goyang, Gyeonggi-do 10408, Republic of Korea; Center for Clinical Trials, Research Institute and Hospital, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang, Gyeonggi-do 10408, Republic of Korea; Cancer Molecular Biology Branch, Division of Cancer Biology, Research Institute of National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang, Gyeonggi-do 10408, Republic of Korea.
Jong-Ho LeeOral Oncology Clinic, Research Institute and Hospital, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang, Gyeonggi-do 10408, Republic of Korea; Department of Oral and Maxillofacial Surgery, Seoul National University Dental Hospital, Dental Research Institute, School of Dentistry, Seoul National University, 101 Daehak-ro, Jongno-gu, Seoul 03080, Republic of Korea.
Dongkwan ShinDepartment of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, 323 Ilsan-ro, Ilsandong-gu, Goyang, Gyeonggi-do 10408, Republic of Korea; Bioinformatics Branch, Division of Cancer Data Science, Research Institute of National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang, Gyeonggi-do 10408, Republic of Korea. Electronic address: dshin@ncc.re.kr.
Ik-Jae KwonDepartment of Oral and Maxillofacial Surgery, Seoul National University Dental Hospital, Dental Research Institute, School of Dentistry, Seoul National University, 101 Daehak-ro, Jongno-gu, Seoul 03080, Republic of Korea. Electronic address: ijkwon@snu.ac.kr.
Sung-Woen ChoiDepartment of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, 323 Ilsan-ro, Ilsandong-gu, Goyang, Gyeonggi-do 10408, Republic of Korea; Oral Oncology Clinic, Research Institute and Hospital, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang, Gyeonggi-do 10408, Republic of Korea; Rare & Pediatric Cancer Branch, Division of Rare and Refractory Cancer, Research Institute of National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang, Gyeonggi-do 10408, Republic of Korea. Electronic address: choiomfs@ncc.re.kr.
Yun-Hee KimMolecular Imaging Branch, Division of Convergence Technology, Research Institute of National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang, Gyeonggi-do 10408, Republic of Korea; Department of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, 323 Ilsan-ro, Ilsandong-gu, Goyang, Gyeonggi-do 10408, Republic of Korea. Electronic address: sensia37@ncc.re.kr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oral cancer is an aggressive malignancy with a survival rate below 50% in advanced stages due to low mutation rates, lack of molecular subtypes, and limited treatment targets. This study presents a pioneering approach to classifying oral cancer subtypes based on the morphology of patient-derived organoids (PDOs) and proposes a therapeutic strategy. We establish 76 cancer and 81 normal PDOs. For cancer PDOs, both manual classification and AI-based scoring are utilized to categorize them into three distinct subtypes: normal-like, dense, and grape-like. These subtypes correlate with unique transcriptomic profiles, genetic mutations, and clinical outcomes, with patients harboring dense and grape-like organoids exhibiting poorer prognoses. Furthermore, drug response assessments of 14 single agents and cisplatin combination therapies identify a synergistic treatment approach for resistant subtypes. This study highlights the potential of integrating morphology-based classification with genomic and transcriptomic analyses to refine oral cancer subtyping and develop effective treatment strategies.

Indexed as

Mouth NeoplasmsOrganoidsCisplatinFemaleGene Expression ProfilingHumansMaleMiddle AgedMutationPrognosisTranscriptomeCisplatincombination therapymorphology analysisoral cancerorganoids

Identifiers

PMID40359934
PMCPMC12147898

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.